Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4422055 | 0.91 | — | — | |
| SCHEMBL6572368 | 0.77 | — | — | |
| SCHEMBL300999 | 0.75 | CYP2C9 (0.32) | TSHR | |
| SCHEMBL9129538 | 0.72 | TSHR (0.39) | TSHRTHPO | |
| SCHEMBL427360 | 0.71 | — | — | |
| SCHEMBL15313305 | 0.69 | TSHR (0.33) | TSHRTHPO | |
| SCHEMBL5462080 | 0.69 | TSHR (0.31) | TSHR | |
| SCHEMBL15173202 | 0.69 | TSHR (0.31) | TSHR | |
| SCHEMBL844108 | 0.67 | — | — | |
| SCHEMBL21954760 | 0.67 | TSHR (0.38) | TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013078554-A1 | COMPOSITIONS OF TIGECYCLINE AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2013-06-06 | — | — | WO | claimed |
| EP-1858504-B1 | CARNITINE-CONTAINING PERITONEAL DIALYSIS SOLUTION HAVING IMPROVED BIOCOMPATIBILITY | SIGMA TAU IND FARMACEUTI (IT) | 2012-01-04 | — | — | EP | claimed |
| US-5876916-A | ADMINISTRATION OF GLYCEROL-PYRUVATE OR HYDROXYACETONE PYRUVATE ESTER WITH BIOCOMPATIBLE CARRIER TO MAMMALS; AS HIGH CALORIE FOOD, ANTICHOLESTEROL AGENTS, ANTIISHEMIC AGENTS, ORGAN PRESERVATIVE, ANTIDIABETIC AGENTS | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-03-02 | — | — | US | claimed |
| EP-0888267-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034856-A1 | NOVEL PYRUVATE COMPOUNDS AND METHODS FOR USE THEREOF | CASE WESTERN RESERVE UNIVERSITY (US) | 1997-09-25 | — | — | WO | claimed |
| WO-2014029016-A1 | COMPOSITIONS COMPRISING A GLYCYLCYCLINE AND A TYROSINE KINASE INHIBITOR FOR TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2014-02-27 | — | — | WO | disclosed |
| WO-2013078554-A1 | COMPOSITIONS OF TIGECYCLINE AND USES THEREOF | UNIVERSITY HEALTH NETWORK (CA) | 2013-06-06 | — | — | WO | disclosed |
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-4158057-A | ADMINISTERING A MIXTURE OF PYRUVATE AND DIHYDROXYACETONE | STANKO RONALD T | 1979-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293702-A1 | Nitric Oxide Enhancing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | TSHR 2087/4885THPO 1810/4885 |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | TSHR 1905/4885THPO 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.